
    
      A 16-week, parallel-group, double-blind, randomized, placebo-controlled, multicenter,
      dose-ranging study to evaluate the efficacy, safety and tolerability of multiple doses and
      multiple treatment regimens of Albiglutide (GSK716155) with Byetta as an open-label active
      reference, in subjects with Type 2 Diabetes Mellitus.
    
  